



Early View

Editorial

Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection

Miguel Meira e Cruz, Masaaki Miyazawa, David Gozal

Please cite this article as: Meira e Cruz M, Miyazawa M, Gozal D. Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection. *Eur Respir J* 2020; in press (<https://doi.org/10.1183/13993003.01023-2020>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection.

Miguel Meira e Cruz^{1*}, Masaaki Miyazawa^{2*}, David Gozal³.

¹Sleep Unit, Cardiovascular Center of University of Lisbon, Lisbon School of Medicine, Lisbon, Portugal;

²Department of Immunology, Faculty of Medicine and Anti-Aging Center, Kindai University, Osaka, Japan

³ Department of Child Health and the Child Health Research Institute, The University of Missouri School of Medicine, Columbia, MO 65201, USA

*- equal contributors

To whom correspondence should be addressed:

David Gozal, MD, MBA, Department of Child Health, University of Missouri School of Medicine, 400 N. Keene Street, Columbia, MO 65201, USA. Tel: +1-573-882-6882.

E-mail: gozald@health.missouri.edu or drdavidgozal@gmail.com

Financial Support: DG is are supported by US National Institutes of Health grants HL130984, AG61824, and HL140548.

Conflicts of interest: The authors declare no conflict of interest in relation with this manuscript.

SARS coronavirus 2 (SARS-CoV-2), the etiologic agent of the pandemic coronavirus disease 2019 (COVID-19), is a newly found member of the Coronaviridae family, and is closely related to, albeit with important differences from, the severe acute respiratory syndrome coronavirus (SARS-CoV) (1). It enters human cells through the binding of surface spike (S) glycoprotein with angiotensin converting enzyme 2 (ACE2) (2-4). The distal S1 subunit of the S protein is responsible for receptor binding while the transmembrane S2 subunit mediates fusion between viral envelope and target cell membrane following proteolytic cleavage by specific cellular enzymes such as serine protease TMPRSS2 for S protein priming (5). As expression levels of ACE2 likely affect the efficiency of virus attachment and entry as well as disease severity (6), and the interactions between viral S protein and ACE2 may directly cause lung injury (7), ACE2 can be a potential target of therapeutic and preventative interventions (8).

Viral infection pathophysiology and role of the circadian clock system

The pathogenicity of viral infections can be affected by host's circadian clock system via two different mechanisms (9-11): (i) direct regulation of viral replication within target cells and (ii) indirect effects on innate and adaptive immune responses. For example, BMAL1, one of the key regulators of the circadian oscillator, directly affects mouse herpesvirus infection in cultured cells and herpes virus replication is significantly enhanced in cells lacking BMAL1 molecule (12). Conversely, acute infection with mouse herpes virus increases BMAL1 expression, which consequently deranges or enhances cell-autonomous rhythms depending at what point in the circadian cycle the infection takes place. Absence of BMAL1 affects the expression of cellular factors involved in protein biosynthesis, endoplasmic reticulum function and vesicular trafficking, all of which are important elements in intracellular replication of coronaviruses (13). Similarly, BMAL1 and REV-ERB α , the nuclear receptor family intracellular transcription factor required for synchronizing and maintaining the peripheral clock (14), influence multiple steps in the hepatitis C virus (HCV) life cycle, including its ability to enter hepatocytes as well as the RNA genome replication of the virus within hepatocytes. Knock-out approaches of *Bmal1* or genetic over-expression or increased REV-ERB activity using synthetic agonists markedly reduce the replication of not only HCV but also other flaviviruses, such

as Dengue and Zika viruses, through disruption of lipid signaling pathways (15).

It is now well established that there is seasonal variation of BMAL1 expression, with lowest values being recorded during winter, and these variations have been implicated in the high prevalence of respiratory viral diseases during winter, particularly in light of the observation that low BMAL1 expression enhances viral virulence (12). When mice were infected with herpes virus at various time-points of the day, significant effects were ascribed to the circadian clock (16). Thus, the circadian clock appears to influence both the infectivity of viruses as well as their ability to replicate inside the host. Furthermore, we surmise that since the circadian clock machinery is intrinsically involved in the regulation of angiotensin pathways, particularly in the transcriptional expression of ACE2, an imputed role for the circadian clock in regulating the infectivity to SARS-CoV-2 is highly probable (17).

The host circadian clock has now been recognized as a major modulator of immune/inflammatory responses in general (18-20), and in particular following respiratory virus infections *in vivo*. It has been shown that an endogenous circadian clock within lung epithelial cells modulates neutrophil recruitment through the chemokine ligand CXCL5 (21). Genetic ablation of BMAL1 in the bronchioles resulted in a disruption of CXCL5 expression rhythms, leading to exaggerated inflammatory responses upon LPS stimulation. Depletion of BMAL1 also resulted in increased morbidity, mortality and virus replication in mice due to a lack of circadian regulation of interferon expression. Importantly, environmental disruption of circadian function by an experimental chronic jet lag model resulted in disrupted temporal expression of BMAL1 in the lungs and increased weight loss after respiratory Sendai virus infection (22).

Time of infection not only changes susceptibility but also predicts survival after influenza virus infection in mice (23). Mice infected at the beginning of their active phase showed higher mortality than those infected at the onset of rest phase. These temporal differences were abolished in mice lacking BMAL1 expression. Interestingly, heightened inflammation was observed in mice infected at the onset of active phase, while the number of natural killer cells was significantly higher in the group infected just prior to the rest phase, suggesting that circadian regulation of innate

immunity plays a major role in these differences. Indeed, depletion of NK cells abolished the time of day differences, indicating that the molecular clock controls host cell responses to influenza virus infection via NK cell functions.

It should be noted, however, that roles of host immune/inflammatory responses in the pathogenesis of influenza virus infection markedly differ from those involved in SARS-CoV-2 infection. Influenza virus replicates vigorously soon after infection and causes massive and sometimes dysregulated production of inflammatory cytokines, potentially leading to the so-called cytokine storm, while replication of SARS-CoV-2 is much slower, and development of lung pathological changes coincides with the activation of the host adaptive immune responses including those of Th17 cells (24).

Nevertheless, it should be emphasized that the timing of host type 1 interferon (IFN-I) responses determines the outcome of respiratory coronavirus infections. Both in MERS- and SARS-CoV infections, early IFN-I signaling is associated with reduced virus replication and mild lung pathology, while delayed IFN-I signaling causes increased infiltration of inflammatory monocytes, heightened proinflammatory cytokine production, and fatal pneumonia (25,26). These heightened inflammatory responses might be further exaggerated in during BMAL1 dysregulation.

Role of ACE2 in SARS-CoV-2 infection

SARS-CoV-2 exhibits high affinity to tissue ACE2. Under normal circumstances, ACE2 is responsible for the inactivation of Angiotensin II (ATII) and therefore plays among other functions, an important role in endothelium and cardiovascular homeostasis (27). Indeed, The ACE-Ang II-AT1R pathway is called the classical renin-angiotensin system (RAS) pathway, and regulates sympathetic nervous system tension, cause vasoconstriction, increase blood pressure, and promote inflammation, fibrosis, and myocardial hypertrophy, while the ACE2-Ang 1-7-Mas proto-oncogene receptor-based axis is viewed as the counter-regulatory RAS pathway, and antagonizes the effects of the classical pathway (27), yet also serves as the tissue receptor for SARS-CoV-2. ACE2 is present in several cellular substrates in the body, but is particularly abundant in the vascular endothelium

including the pulmonary vasculature, which may explain the predilection of SARS-CoV-2 to the lung. In this context, several hypotheses have been raised revolving around the overall effect of ACE1 or angiotensin receptor blockers (ARB) on COVID-19 infections. Putative beneficial results would consist of ACE2 receptor blockade, thereby restricting the viral entry load into organs such as the lungs, and modulation of inflammatory response by these pharmacological agents. However, a potential retrograde feedback mechanism leading to up-regulation of ACE2 receptors cannot be excluded. As such, notwithstanding the a priori beneficial effects of ACE1/ARB on SARS-CoV infection, we cannot extrapolate them to SARS-CoV-2 causing COVID-19. Furthermore, when conditions such as aging, systemic hypertension, and other cardiovascular diseases are present, increased ATII levels lead to lower ACE2 activity, and increased inflammation, and could position such patients at increased risk for deterioration of their underlying disease and more severe adverse outcomes due to inactivation of the already reduced ACE2 by SARS-CoV-2 (28).

Putative role of circadian clocks in the pathophysiology of SARS-CoV-2 infection

As mentioned, SARS-CoV-2 cellular receptor ACE2 is expressed on the outer membranes of tracheal, bronchiolar and lung alveolar epithelial cells, enterocytes in the small intestine, vascular endothelial and smooth muscle cells, and epithelial cells of renal tubules along with other mucosal tissues (29). Importantly, ACE2 functions as a negative regulator of the renin-angiotensin system by cleaving angiotensin II (AngII) at its C-terminus and creating vasodilating angiotensin 1-7 (Ang(1-7))(7). A lack of ACE2 is associated with increased lung injury upon acid aspiration, and this detrimental effect was markedly ameliorated in mice genetically lacking the lung epithelial angiotensin II receptor 1a (30). Further, administration of recombinant ACE2 protected ACE2-deficient as well as wild-type mice from the acute lung injury. Thus, AngII functions as proinflammatory mediator while Ang(1-7) exhibits anti-inflammatory functions (6). As the expression of ACE2 is reduced in aged individuals, its dual function as SARS-CoV2 entry receptor and as the enzyme that converts proinflammatory AngII into anti-inflammatory Ang(1-7) may account for the less frequent infection with SARS-CoV2, but more severe disease outcome in older individuals (6).

Possible circadian changes in the expression of ACE2 in the lungs have not been reported until now, but AngII is known to affect the rhythmic expression of Per2, one of key repressors that constitute the feedback loop of mammalian clock circuitry in the suprachiasmatic nuclei (31). Further, levels of ACE expression in the heart show distinct diurnal changes (32) and AngII induces changes in the expression of circadian genes in vascular cells (33), while changes in BMAL1 expression also affect the expression of angiotensinogen and resting blood pressure in perivascular adipose tissues (34). Thus, it is conceivable that lung expression of ACE2 will also manifest circadian changes through cell autonomous regulations and through indirect effects of circadian changes in renin-angiotensin system. Considering that the more severe manifestations of SARS-Cov-2 infection include acute respiratory distress syndrome (ARDS), a condition characterized by enhanced vascular permeability in the lung (35,36), it would be important to also consider the role of the pulmonary endothelium and its cognate expression of ACE2 as a potential target for the virus-induced ARDS (37,38). Of note, a putative adjuvant role for melatonin has been recently proposed for ARDS in the setting of SARS-Cov-2 infection (39). Furthermore, the higher propensity for COVID-19 to manifest in obese patients and in males, might be also explained by the significant inter-dependent role played by ACE2 in obesity (40-43), and the downstream systemic inflammation induced by this highly prevalent condition (44), and the sexual dimorphism of such effects (45).

Sleep and SARS-Cov 2 infection

Sleep, a circadian behavioral manifestation of major regulatory homeostatic mechanisms such as those associated with immunity, has also been shown to interact with host defenses at the molecular and cellular levels. Indeed, extensive literature has indicated the important role of homeostatic sleep in innate and adaptive immunity (46). Furthermore, there are clear reciprocal dependencies between sleep duration and quality and the immune responses against viral, bacterial, and parasitic pathogens, the latter altering in turn sleep patterns (46). Thus, it is likely that improved sleep quality and duration in the population may mitigate the propagation and severity of disease induced by SARS-Cov-2 infection. Interestingly and potentially relevant to the SARS-Cov-2-ACE2 pathophysiological interdependency, Carhan *et al* observed in a drosophila model that adult flies lacking ACER (an

ACE2 homologue in *Drosophila melanogaster*) or those treated with peptidase inhibitors experienced disrupted night-time sleep (47). We are unaware of any specific studies examining the effects of sleep on SARS-Cov-2 infection ~~or any p~~. Nonetheless, we should remark that coronaviruses are found with increased frequency in the tonsillar tissues of children suffering from obstructive sleep apnea (48).

Potential Clinical Implications

As mentioned above, it is unclear how disrupted or insufficient sleep may affect SARS-Cov2 infection rates and the severity of its clinical manifestations. Typical symptoms of acute lung injury (ALI) include dyspnea, hypoxemia and pulmonary edema which may deteriorate into the severe acute respiratory syndrome (SARS). The cell-based pathological mechanisms of such progression involve activation of immune-inflammatory cascades resulting in disruption of the alveolar- capillary barrier (38). This immuno-inflammatory activation is influenced by the circadian clock, and therefore deregulation of circadian rhythms such as in night shift workers or social jetlag could play a disease-specific role by altering the susceptibility to infection or modifying the clinical manifestations of COVID-19 syndrome. It would be of paramount importance to establish the prevalence and severity of SARS-CoV-2 infection in the population while ensuring that adequate information regarding their sleep habits and circadian activities would be appropriately incorporated. Furthermore, since ACE2, which may be regulated by clock activity, was shown to have a protective effect through suppression of apoptosis of pulmonary endothelial cells, it is possible that chronobiological interventions may mitigate the progression of lung injury, if such interventions occur in a very early stage of the infection (49). Alternatively, in light of clinical studies showing the relevance of chronoadequacy of ACE inhibitor therapy on hypertension (50), it is possible that administration of such agents in the context of SARS-Cov-2 infection may require more precise alignment with the patient circadian clock status (51), even though the evidence supporting such pharmacological treatment is doubtful at best (52).

Based on aforementioned considerations, the presence of underlying sleep disorders, such as obstructive sleep apnea (OSA), could be viewed as a facilitator of SARS-Cov2 infection, in light of

the well-established alterations of the RAS in this highly prevalent disease (53-58). It will be important to evaluate whether patients with OSA were more likely to be infected, and whether the clinical outcomes among those infected with the SARS-Cov2 were less favorable.

In summary, the unique potential links between SARS-Cov-2 and circadian rhythms and sleep have been reviewed, and suggest the possibility that both of these homeostatic processes may significantly modify the susceptibility to infection as well as the overall clinical manifestation of the disease. Therefore, implementation of healthy sleep measures as a protective strategy against infection, and early detection of patients at risk for more severe disease (e.g., night-shift workers or patients with OSA) may enable improved implementation of supportive measures and lead to better outcomes,

Figure 1 legend: Possible links between SARS-CoV-2 infection and circadian clock system. Blue lines indicate known links between cellular BMAL1 expression and replication of or responses to other viruses. ACE2 expression on respiratory epithelial cells may be regulated through type 1 interferon (IFN-I)-induced mechanisms (59). As surface S glycoprotein of SARS-CoV-2 binds protease domain of ACE2, virus attachment may directly compete with the processing of AngII to Ang(1-7), a negative regulator of the renin-angiotensin system. AngII is known to be proinflammatory, while Ang(1-7) is anti-inflammatory. IFN-I signaling in the late phase of coronavirus infection induces exaggerated cytokine production and more severe lung injury. BMAL1 regulates IFN-I and chemokine CXCL5 production. AngII is known to affect the central clock system in the suprachiasmatic nuclei (SCN) through its effect on Per2 levels.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020 Feb 20;382(8):727-733.
2. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*. 2020 Mar 13;367(6483):1260-1263.
3. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science*. 2020 Mar 27;367(6485):1444-1448.
4. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 2020 Mar 6. pii: S0092-8674(20)30262-2.
5. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020 Mar 4. pii: S0092-8674(20)30229-4. doi: 10.1016/j.cell.2020.02.052. [Epub ahead of print] PubMed PMID: 32142651.
6. AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. *JAMA Cardiol*. 2020 Apr 3. doi: 10.1001/jamacardio.2020.1329. [Epub ahead of print] PubMed PMID: 32242886.
7. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med*. 2020 Apr;46(4):586-590.
8. Tai, W., He, L., Zhang, X. Pu J, Voronin D, Jiang S, Zhou Y, Du L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. *Cell Mol Immunol*. 2020 Mar 19. doi: 10.1038/s41423-020-0400-4. [Epub ahead of print] PubMed PMID: 32203189.
9. Zhuang X, Rambhatla SB, Lai AG, McKeating JA. Interplay between circadian clock and viral infection. *J Mol Med (Berl)*. 2017 Dec;95(12):1283-1289
10. Mazzocchi G, Vinciguerra M, Carbone A, Relógio A. The Circadian Clock, the Immune System, and Viral Infections: The Intricate Relationship Between Biological Time and Host-Virus Interaction. *Pathogens*. 2020 Jan 27;9(2). pii: E83.
11. Costantini C, Renga G, Sellitto F, Borghi M, Stincardini C, Pariano M, Zelante T, Chiarotti F, Bartoli A, Mosci P, Romani L, Brancorsini S, Bellet MM. Microbes in the Era of Circadian Medicine. *Front Cell Infect Microbiol*. 2020 Feb 5;10:30.
12. Edgar RS, Stangherlin A, Nagy AD, Nicoll MP, Efstathiou S, O'Neill JS, Reddy AB. Cell autonomous regulation of herpes and influenza virus infection by the circadian clock. *Proc Natl Acad Sci U S A*. 2016 Sep 6;113(36):10085-90.
13. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. *Methods Mol Biol*. 2015;1282:1-23.
14. Yin L, Wang J, Klein PS, Lazar MA. Nuclear receptor Rev-erb α is a critical lithium-sensitive component of the circadian clock. *Science*. 2006; 17;311(5763):1002-5.

15. Zhuang X, Magri A, Hill M, Lai AG, Kumar A, Rambhatla SB, Donald CL, Lopez-Clavijo AF, Rudge S, Pinnick K, Chang WH, Wing PAC, Brown R, Qin X, Simmonds P, Baumert TF, Ray D, Loudon A, Balfe P, Wakelam M, Butterworth S, Kohl A, Jopling CL, Zitzmann N, McKeating JA. The circadian clock components BMAL1 and REV-ERB α regulate flavivirus replication. *Nat Commun.* 2019 Jan 22;10(1):377.
16. Matsuzawa, T.; Nakamura, Y.; Ogawa, Y.; Ishimaru, K.; Goshima, F.; Shimada, S.; Nakao, A.; Kawamura, T. Differential day-night outcome to HSV-2 cutaneous infection. *J. Invest. Dermatol.* 2018; 138: 233–236.
17. Herichova I, Zsoldosova K, Vesela A, Zeman M. Effect of angiotensin II infusion on rhythmic clock gene expression and local renin-angiotensin system in the aorta of Wistar rats. *Endocr Regul.* 2014 Jul;48(3):144-51.
18. Murakami M, Tognini P. The circadian clock as an essential molecular link between host physiology and microorganisms. *Front Cell Infect Microbiol.* 2020 Jan 22;9:469.
19. Tognini P, Thaïss CA, Elinav E, Sassone-Corsi P. Circadian coordination of antimicrobial responses. *Cell Host Microbe.* 2017 Aug 9;22(2):185-192.
20. Nguyen KD, Fentress SJ, Qiu Y, Yun K, Cox JS, Chawla A. Circadian gene *bmal1* regulates diurnal oscillations of *ly6c(hi)* inflammatory monocytes. *Science* 2013; 341:1483–1488
21. Pick R., He W, Chen CS, Scheiermann C. Time-of-day-dependent trafficking and function of leukocyte subsets. *Trends Immunol.* 2019;40:524–537.
22. Arjona A, Sarkar DK. Evidence supporting a circadian control of natural killer cell function. *Brain Behav. Immun.* 2006, 20, 469–476.
23. Gibbs J, Ince L, Matthews L, Mei J, Bell T, Yang N, Saer B, Begley N, Poolman T, Pariollaud M, Farrow S, DeMayo F, Hussell T, Worthen GS, Ray D, Loudon A. An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action. *Nat Med.* 2014 Aug;20(8):919-26.
24. Ehlers A, Xie W, Agapov E, Brown S, Steinberg D, Tidwell R, Sajol G, Schutz R, Weaver R, Yu H, Castro M, Bacharier LB, Wang X, Holtzman MJ, Haspel JA. BMAL1 links the circadian clock to viral airway pathology and asthma phenotypes. *Mucosal Immunol.* 2018 Jan;11(1):97-111.
25. Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, Sompallae R, McCray PB Jr, Meyerholz DK, Perlman S. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. *J Clin Invest.* 2019;130:3625-3639.
26. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S. Dysregulated Type I Interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-Infected Mice. *Cell Host Microbe.* 2016; 19(2): 181–193.
27. Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, Lavandero S. Counter-regulatory renin-angiotensin system in cardiovascular disease. *Nat Rev Cardiol.* 2020;17(2):116-129.
28. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. *Circulation.* 2020 Apr 15.
doi:10.1161/CIRCULATIONAHA.120.047549. [Epub ahead of print] PubMed PMID: 32293910.

29. Sengupta S, Tang SY, Devine JC, Anderson ST, Nayak S, Zhang SL, Valenzuela A, Fisher DG, Grant GR, López CB, FitzGerald GA. Circadian control of lung inflammation in influenza infection. *Nat Commun*. 2019 Sep 11;10(1):4107.
30. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 2020 Feb 18. pii: S2213-2600(20)30076-X. doi: 10.1016/S2213-2600(20)30076-X. [Epub ahead of print] Erratum in: *Lancet Respir Med*. 2020 Feb 25;:. PubMed PMID: 32085846.
31. Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. *EMBO J*. 2005 Apr 20;24(8):1634-43.
32. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature*. 2005 Jul 7;436(7047):112-6.
33. Naito Y, Tsujino T, Matsumoto M, Okuda S, Sakoda T, Ohyanagi M, Masuyama T. The mechanism of distinct diurnal variations of renin-angiotensin system in aorta and heart of spontaneously hypertensive rats. *Clin Exp Hypertens*. 2009;31(8):625-38.
34. Nonaka H, Emoto N, Ikeda K, Fukuya H, Rohman MS, Raharjo SB, Yagita K, Okamura H, Yokoyama M. Angiotensin II induces circadian gene expression of clock genes in cultured vascular smooth muscle cells. *Circulation*. 2001 Oct 9;104(15):1746-8.
35. Chang L, Xiong W, Zhao X, Fan Y, Guo Y, Garcia-Barrio M, Zhang J, Jiang Z, Lin JD, Chen YE. Bmal1 in Perivascular Adipose Tissue Regulates Resting-Phase Blood Pressure Through Transcriptional Regulation of Angiotensinogen. *Circulation*. 2018;138(1):67-79.
36. Villar J, Zhang H, Slutsky AS. Lung Repair and Regeneration in ARDS: Role of PECAM1 and Wnt Signaling. *Chest*. 2019 Mar;155(3):587-594.
37. Wang T, Gross C, Desai AA, Zemskov E, Wu X, Garcia AN, Jacobson JR, Yuan JX, Garcia JG, Black SM. Endothelial cell signaling and ventilator-induced lung injury: molecular mechanisms, genomic analyses, and therapeutic targets. *Am J Physiol Lung Cell Mol Physiol*. 2017 Apr 1;312(4):L452-L476.
38. Fedson DS, Opal SM, Rordam OM. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection. *mBio*. 2020 Mar 20;11(2). pii: e00398-20.
39. Kim J, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, Yoo CG, Kim YW, Han SK, Lee SM. Effect of Renin-Angiotensin System Blockage in Patients with Acute Respiratory Distress Syndrome: A Retrospective Case Control Study. *Korean J Crit Care Med*. 2017 May;32(2):154-163.
40. Slamkova M, Zorad S, Krskova K. Alternative renin-angiotensin system pathways in adipose tissue and their role in the pathogenesis of obesity. *Endocr Regul*. 2016;50(4):229-240.
41. Than A, Leow MK, Chen P. Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways. *J Biol Chem*. 2013;288(22):15520-31.
42. Pinheiro TA, Barcala-Jorge AS, Andrade JMO, Pinheiro TA, Ferreira ECN, Crespo TS, Batista-Jorge GC, Vieira CA, Lelis DF, Paraíso AF, Pinheiro UB, Bertagnolli M, Albuquerque CJB, Guimarães ALS, de Paula AMB, Caldeira AP, Santos SHS. Obesity

- and malnutrition similarly alter the renin-angiotensin system and inflammation in mice and human adipose. *J Nutr Biochem*. 2017;48:74-82.
43. Santos SH, Andrade JM. Angiotensin 1-7: a peptide for preventing and treating metabolic syndrome. *Peptides*. 2014;59:34-41.
 44. Lelis DF, Freitas DF, Machado AS, Crespo TS, Santos SHS. Angiotensin-(1-7), Adipokines and Inflammation. *Metabolism*. 2019;95:36-45.
 45. Gupte M, Thatcher SE, Boustany-Kari CM, Shoemaker R, Yiannikouris F, Zhang X, Karounos M, Cassis LA. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. *Arterioscler Thromb Vasc Biol*. 2012;32(6):1392-9.
 46. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, Liu C, Reiter RJ. COVID-19: Melatonin as a potential adjuvant treatment. *Life Sci*. 2020 Mar 23;117583. doi: 10.1016/j.lfs.2020.117583. [Epub ahead of print] Review. PubMed PMID: 32217117.
 47. Irwin MR, Opp MR. Sleep Health: Reciprocal Regulation of Sleep and Innate Immunity. *Neuropsychopharmacology*. 2017;42(1):129-155.
 48. Carhan A, Tang K, Shirras CA, Shirras AD, Isaac RE. Loss of angiotensin-converting enzyme-related (ACER) peptidase disrupts night-time sleep in adult *Drosophila melanogaster*. *J Exp Biol*. 2011;214(4):680-686.
 49. Yeshuroon-Koffler K, Shemer-Avni Y, Keren-Naus A, Goldbart AD. Detection of common respiratory viruses in tonsillar tissue of children with obstructive sleep apnea. *Pediatr Pulmonol*. 2015;50(2):187-95.
 50. Bao H, Gao F, Xie G, Liu Z. Angiotensin-converting enzyme 2 inhibits apoptosis of pulmonary endothelial cells during acute lung injury through suppressing MIR-4262. *Cell Physiol Biochem* 2015; 37:759-767.
 51. Hermida R, Ayala D. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension. Improved blood pressure control with bedtime dosing. *Hypertension* 2009; 54:40-46.
 52. Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. *Curr Cardiol Rep*. 2020 Apr 14;22(5):31.
 53. Braun R, Kath WL, Iwanaszko M, Kula-Eversole E, Abbott SM, Reid KJ, Zee PC, Allada R. Universal method for robust detection of circadian state from gene expression. *Proc Natl Acad Sci U S A*. 2018 Sep 25;115(39):E9247-E9256.
 54. Nicholl DDM, Hanly PJ, Zalucky AA, Mann MC, MacRae JM, Poulin MJ, Handley GB, Sola DY, Ahmed SB. CPAP Therapy Delays Cardiovascular Reactivation and Decreases Arterial Renin-Angiotensin System Activity in Humans With Obstructive Sleep Apnea. *J Clin Sleep Med*. 2018 Sep 15;14(9):1509-1520.
 55. Wang W, Song A, Zeng Y, Chen X, Zhang Y, Shi Y, Lin Y, Luo W. Telmisartan protects chronic intermittent hypoxic mice via modulating cardiac renin-angiotensin system activity. *BMC Cardiovasc Disord*. 2018 Jul 3;18(1):133.
 56. Khayat RN, Varadharaj S, Porter K, Sow A, Jarjoura D, Gavrilin MA, Zweier JL. Angiotensin Receptor Expression and Vascular Endothelial Dysfunction in Obstructive Sleep Apnea. *Am J Hypertens*. 2018 Feb 9;31(3):355-361.
 57. Jin ZN, Wei YX. Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system. *J Geriatr Cardiol*. 2016 May;13(4):333-43.
 58. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pépin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A.

Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med.* 2019 Aug;7(8):687-698.

59. Ziegler C, Allon SJ, Nyquist SK, Mbanjo I, Miao VN, Cao Y, Yousif AS, Bals J, Hauser BM, Feldman J, Muus C, Wadsworth II MH, Kazer S, Hughes TK, Doran B, Gatter GJ, Vukovic M, Tzouanas CN, Taliaferro F, Guo Z, Wang JP, Dwyer DF, Buchheit KM, Boyce J, Joshua Barrett NA, Laidlaw TM, Carroll SL, Colonna L, Tkachev V, Yu A, Zheng HB, Gideon HP, Winchell CG, Lin PL, Berger B, Leslie A, Flynn JL, Fortune SM, Finberg RW, Kean L, Garber M, Schmidt A, Lingwood D, Shalek AK, Ordovas-Montanes J, Lung Biological Network, HCA. SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues. CELL-D-20-00767. Available at SSRN: <https://ssrn.com/abstract=3555145> or <http://dx.doi.org/10.2139/ssrn.3555145>

Figure 1

